Discussions
Discussions
Ksmiles123 Check-In 08/09/2025
Hello! It will be an exciting, interesting week ahead for Insmed as the FDA will be reviewing Brensocatib, on August 12th. Brensocatib will be the first drug for Bronchiectasis when the approval process is completed . Bronchiectasis is finally getting increased awareness, research leading to the development of more drug/ therapies. The article below reviews the process: https://pharmaphorum.com/news/fda-starts-review-first-bronchiectasis-drug-candidate
Replies
Thanks, Katie. The last paragraph of the article mentions additional medications that might soon be available, a reason to be hopeful.
Other drugs in development for bronchiectasis include Armata Pharma’s AP-PA02 – a bacteriophage-based therapy for non-CF bronchiectasis caused by chronic Pseudomonas aeruginosa infections, which recently generated positive phase 2 data in the Tailwind study – along with Boehringer Ingelheim's cathepsin C Inhibitor BI-1291583 (phase 2), Sanofi's anti-IL-33 antibody itepekimab (phase 2), and Chiesi's human neutrophil elastase inhibitor CHF-633 (phase 1/2)
Marsrocket,
You are most welcome! I hope that you are getting some relief with your new treatment plan in place. Thank you for posting the other drugs in the pipeline .
It is not our intention to serve as a substitute for medical advice and any content posted should not be used for medical advice, diagnosis or treatment. We make every effort to support our members, our medical professionals cannot and will not provide a diagnosis or suggest a specific medication; those decisions should be left to your personal medical team. While we encourage individuals to share their personal experiences with COPD, please consult a physician before making changes to your own COPD management plan.
Community posts are monitored by the 360social Community Manager, as well as staff respiratory therapists, educators, and other medical professionals.